Indivior Pharmaceuticals

INDV

Market cap $4.78B

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.

INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.

Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.

Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential.

INDV, RNW, LCUT, NTCT and TNK passed a screen for efficiency, outperforming industry peers on inventory, receivables, assets and margins.